home / stock / apls / apls news

APLS News and Press, Apellis Pharmaceuticals Inc.

Stock Information
Company Name: Apellis Pharmaceuticals Inc.
Stock Symbol: APLS
Market: NASDAQ
Menu
APLS APLS Quote APLS Short APLS News APLS Articles APLS Message Board
Get APLS Alerts

News, Short Squeeze, Breakout and More Instantly...
APLS - Apellis falls as EU experts decline to back eye disorder therapy

2024-06-28 10:19:27 ET More on Apellis Pharmaceuticals Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks Apellis Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation Apellis Pharmaceuticals, Inc. (APLS) Q1 2024 Earnings Call Transc...
APLS - Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU

WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the marketing authorization application (MAA) of i...

APLS - When (APLS) Moves Investors should Listen

2024-06-19 19:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

APLS - SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)

SYFOVRE is the only approved GA treatment to demonstrate a visual function benefit in a prespecified endpoint Data presented at the Clinical Trials at the Summit Meeting WALTHAM, Mass., June 10, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announ...
APLS - Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference

WALTHAM, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024, at 4:00 p.m. ET. The live conference webcas...

APLS - Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

2024-06-04 14:07:57 ET Summary Annexon, Inc. primary endpoint met with statistical significance in phase 3 Bangladesh and Philippines study, using ANX005 for the treatment of patients with Guillain-Barré syndrome. Results from RWS IGOS phase 3 study, using ANX005 for the trea...

APLS - Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo

2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...
APLS - Apellis Pharma up on phase 2 data for kidney disease treatment pegcetacoplan

2024-05-24 13:12:20 ET More on Apellis Pharmaceuticals Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks Apellis Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation Apellis Pharmaceuticals, Inc. (APLS) Q1 2024 Earnings Call Transc...

APLS - Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress

Rapid reduction in disease activity seen at 12 weeks was sustained at one year 55% of patients showed zero C3c staining intensity, indicating that C3c deposits were cleared Highlighted as late-breaking oral presentation at the European Renal Association (ERA) Congress WA...

APLS - APLS Price Target Alert: $48.00. Issued by Wells Fargo

2024-05-23 08:00:11 ET Derek Archila from Wells Fargo issued a price target of $48.00 for APLS on 2024-05-23 07:10:00. The adjusted price target was set to $48.00. At the time of the announcement, APLS was trading at $43.6. The overall price target consensus is at $76.38...
Next 10